- Home
- AMPL vs INBX Comparison
AMPL vs INBX Comparison
Compare AMPL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMPL | INBX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.7M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AMPL | INBX |
|---|---|---|
| Price | $6.21 | $82.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | $13.42 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.5M | 199.0K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,214,000.00 | $1,300,000.00 |
| Revenue This Year | $17.43 | N/A |
| Revenue Next Year | $14.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 14.68 | ★ 550.00 |
| 52 Week Low | $5.51 | $10.90 |
| 52 Week High | $14.27 | $94.57 |
Technical Indicators
Market Signals| Indicator | AMPL | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 65.68 |
| Support Level | N/A | $71.31 |
| Resistance Level | $7.89 | $85.97 |
| Average True Range (ATR) | 0.39 | 5.44 |
| MACD | -0.05 | 2.36 |
| Stochastic Oscillator | 42.53 | 96.34 |
Price Performance
Historical ComparisonAbout AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.